CJC-1295 with DAC 5mg

Description

CJC-1295 with DAC Peptide Overview

CJC-1295 with DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH) bearing a Drug Affinity Complex (DAC). The DAC technology dramatically extends its half-life, making it one of the most studied long-duration GHRH analogs in research.

GHRH Receptor Activation

The GHRH portion of CJC-1295 binds GHRH receptors on the anterior pituitary and is studied for stimulating the synthesis and release of endogenous growth hormone and downstream IGF-1.

Extended Half-Life via DAC

The Drug Affinity Complex binds covalently to serum albumin, protecting the peptide from breakdown and extending its circulation time. This prolonged, sustained GHRH signaling is a central subject of CJC-1295 research.

Sustained GH and IGF-1 Elevation

Research on CJC-1295 with DAC focuses on its ability to produce a sustained elevation of growth hormone and IGF-1 rather than the short pulses of native GHRH.

Specifications

• CAS Number: 863288-34-0
• Molecular Formula: C152H252N44O42
• Molar Mass: 3647.15 g/mol
• Class: Long-acting GHRH analog with Drug Affinity Complex (peptide)
• Storage: Refrigerate after reconstitution.
• Form: Lyophilized powder in a sterile glass vial.
• Purity: Minimum 99%
• Quantity: 5mg per vial
• Color: White

Important Note: This product is intended solely for in vitro laboratory research by licensed professionals. It is not approved by the FDA for human or animal use and should not be misbranded, misused, or mislabeled as a drug, food, supplement, or cosmetic.

References:

1. Teichman S.L. et al. – Prolonged stimulation of GH and IGF-1 by CJC-1295 – Journal of Clinical Endocrinology & Metabolism
2. GHRH analogs and Drug Affinity Complex technology – Clinical Pharmacokinetics
3. Growth hormone-releasing hormone receptor signaling – Endocrine Reviews